Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 537306, 7 pages
Review Article

Pharmacological Treatments in Gambling Disorder: A Qualitative Review

1Department of Neuroscience and Imaging, University “G. d’Annunzio”, Chieti, Italy
2Department of Psychiatry, Drug Addiction Unit, Catholic University Medical School, Rome, Italy

Received 26 February 2014; Accepted 23 April 2014; Published 18 May 2014

Academic Editor: Ornella Corazza

Copyright © 2014 Matteo Lupi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Gambling disorder (GD) is a psychiatric condition associated with both social and family costs; DSM-5 currently includes GD among addictive disorders. Despite the high burden of this condition, to date there are no treatment guidelines approved by Food and Drug Administration (FDA). Purpose of this paper is to offer a qualitative overview about the different pharmacologic agents used for the treatment of GD. Our analysis, conducted on a final selection of 75 scientific papers, demonstrates that a variety of pharmaceutical classes have been utilised, with different results. Published data, although limited by brief duration of the studies and small number of enrolled subjects, shows mixed evidence for serotonergic antidepressants, opioid antagonists, and mood stabilizers. Other compounds, such as glutamatergic agents and psychostimulants, deserve further studies.